Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stefano Luminari

Showing results (61-70 of 210) with videos related to

Pageof 21
Sort By:
Annals of Hematology|September 18, 2010
Phase II fludarabine and cyclophosphamide for the treatment of indolent B cell non-follicular lymphomas: final results of the LL02 trial of the Gruppo Italiano per lo Studio dei Linfomi (GISL)Andrea Ferrario, Francesco Merli, Stefano Luminari, et al.
Leukemia & Lymphoma|January 7, 2006
Vinorelbine, gemcitabine, procarbazine and prednisone (ViGePP) as salvage therapy in relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL): results of a phase II study conducted by the Gruppo Italiano per lo Studio dei LinfomiNicola Di Renzo, Maura Brugiatelli, Antonella Montanini, et al.
Leukemia Research|February 12, 2013
Monocytosis has adverse prognostic significance and impacts survival in patients with T-cell lymphomasAlessia Bari, Tamar Tadmor, Stefano Sacchi, et al.
British Journal of Haematology|July 30, 2013
Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysisSamantha Pozzi, Luigi Marcheselli, Alessia Bari, et al.
Haematologica|December 26, 2015
Brentuximab vedotin followed by ABVD +/- radiotherapy in patients with previously untreated Hodgkin lymphoma: final results of a pilot phase II studyMassimo Federico, Stefano Luminari, Cinzia Pellegrini, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 27, 2014
Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patientsMichel Meignan, Myriam Sasanelli, René Olivier Casasnovas, et al.
Annals of Hematology|April 21, 2020
Germinotropic lymphoproliferative disorder: a systematic reviewMagda Zanelli, Maurizio Zizzo, Alessandra Bisagni, et al.
Haematologica|September 2, 2004
Quality of life assessment in elderly patients with aggressive non-Hodgkin's Lymphoma treated with anthracycline-containing regimens. Report of a prospective study by the Intergruppo Italiano LinfomiFrancesco Merli, Marilena Bertini, Stefano Luminari, et al.
British Journal of Haematology|May 16, 2020
Long-term results of the MCL01 phase II trial of rituximab plus HyperCVAD alternating with high-dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphomaFulvio Massaro, Yana Stepanishyna, Martina Manni, et al.
Hemasphere|April 20, 2026
Dynamics of complete responses (CRs) in patients with relapsed or refractory follicular lymphoma (R/R FL) treated with odronextamab in the ELM-2 studyStefano Luminari, Ana Jiménez-Ubieto, Geoffrey Chong, et al.
Pageof 21

Showing results (61-70 of 210) with videos related to

Sort By:
Pageof 21
Annals of Hematology|September 18, 2010
Phase II fludarabine and cyclophosphamide for the treatment of indolent B cell non-follicular lymphomas: final results of the LL02 trial of the Gruppo Italiano per lo Studio dei Linfomi (GISL)Andrea Ferrario, Francesco Merli, Stefano Luminari, et al.
Leukemia & Lymphoma|January 7, 2006
Vinorelbine, gemcitabine, procarbazine and prednisone (ViGePP) as salvage therapy in relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL): results of a phase II study conducted by the Gruppo Italiano per lo Studio dei LinfomiNicola Di Renzo, Maura Brugiatelli, Antonella Montanini, et al.
Leukemia Research|February 12, 2013
Monocytosis has adverse prognostic significance and impacts survival in patients with T-cell lymphomasAlessia Bari, Tamar Tadmor, Stefano Sacchi, et al.
British Journal of Haematology|July 30, 2013
Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysisSamantha Pozzi, Luigi Marcheselli, Alessia Bari, et al.
Haematologica|December 26, 2015
Brentuximab vedotin followed by ABVD +/- radiotherapy in patients with previously untreated Hodgkin lymphoma: final results of a pilot phase II studyMassimo Federico, Stefano Luminari, Cinzia Pellegrini, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 27, 2014
Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patientsMichel Meignan, Myriam Sasanelli, René Olivier Casasnovas, et al.
Annals of Hematology|April 21, 2020
Germinotropic lymphoproliferative disorder: a systematic reviewMagda Zanelli, Maurizio Zizzo, Alessandra Bisagni, et al.
Haematologica|September 2, 2004
Quality of life assessment in elderly patients with aggressive non-Hodgkin's Lymphoma treated with anthracycline-containing regimens. Report of a prospective study by the Intergruppo Italiano LinfomiFrancesco Merli, Marilena Bertini, Stefano Luminari, et al.
British Journal of Haematology|May 16, 2020
Long-term results of the MCL01 phase II trial of rituximab plus HyperCVAD alternating with high-dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphomaFulvio Massaro, Yana Stepanishyna, Martina Manni, et al.
Hemasphere|April 20, 2026
Dynamics of complete responses (CRs) in patients with relapsed or refractory follicular lymphoma (R/R FL) treated with odronextamab in the ELM-2 studyStefano Luminari, Ana Jiménez-Ubieto, Geoffrey Chong, et al.
Pageof 21